Skip to main content

Table 1 Maximum Symptom Severity at Reactive Doses During Screening and Exit DBPCFC in PALISADE

From: Post hoc analysis examining symptom severity reduction and symptom absence during food challenges in individuals who underwent oral immunotherapy for peanut allergy: results from three trials

Maximum symptom severity (Grade)

PTAH

Placebo

Screening DBPCFCa

n (%)

Exit (WRb)

DBPCFC n (%)

Screening DBPCFCa n (%)

Exit (WRb) DBPCFC n (%)

None (0)

0 (0)

284 (76.3)

0 (0)

29 (23.4)

Mild (1)

109 (29.3)

11 (3)

35 (28.2)

44 (35.5)

Moderate (2)

216 (58.1)

1 (0.3)

80 (64.5)

38 (30.6)

Severe (3)

47 (12.6)

0 (0)

9 (7.3)

5 (4)

Missing

0 (0)

76 (20.4)

0 (0)

8 (6.5)

Total

372 (100)

372 (100)

124 (100)

124 (100)

  1. aParticipants were required to experience dose-limiting symptoms at or before 100 mg
  2. bWR, or “with replacement,” indicates participants who reacted to a lower dose during the exit DBPCFC compared with the screening DBPCFC and assigned with their maximum symptom severity during the screening DBPCFC reactive dose—this only occurred in the placebo group. The exit WR analysis also reports missing data and dropouts; the analysis does not replace missing data or dropouts
  3. DBPCFC double-blind, placebo-controlled food challenge, PTAH peanut (Arachis hypogaea) allergen powder-dnfp, WR with replacement